|Articles|February 2, 2016

Catalent Pharma Solutions to Showcase at InformEx 2016

Catalent Pharma Solutions’ technical project manager, Elanor Pinto-Cocozza, PhD, will present at InformEx 2016.

Catalent Pharma Solutions, a provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health, and animal health products, announced that Elanor Pinto-Cocozza, PhD, technical project manager, Catalent Micron Technologies, will be presenting at the InformEx Conference, in New Orleans, LA, on February 2–4, 2016.

Dr. Pinto-Cocozza’s presentation on Wednesday, February 3rd is entitled How Preformulation and Formulation Development can Optimize API Properties for Better Drug Design, and will discuss how accurate early-stage prediction of compounds’ physicochemical and biopharmaceutical properties can be beneficial in the selection of suitable technologies that optimize bioavailability, safety, and stability of any new chemical entity.

The presentation will also demonstrate how working with development partners with expertise in preformulation and formulation development can facilitate streamlined design of pharmacokinetic and efficacy/toxicity studies, leading to pharmacologically effective and developable candidates to reach the clinic, and ultimately the market, faster.

Catalent will also be exhibiting at InformEx, Booth 411, where it will showcase a broad range of its delivery technologies and solutions designed to increase bioavailability and drug efficacy, including its comprehensive particle size engineering capabilities.

Source: Catalent


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.